Dr. Husseini Manji’s affiliations are quite the laundry list: a professor of psychiatry at the University of Oxford with adjunct and visiting positions at Yale and Duke, as well as serving as co-chair of the UK government’s mental health mission. But it’s his earlier work as a pioneer in the development of rapid-acting antidepressants that concerns this interview, with Manji’s role in esketamine’s…

Source

Previous articleJosh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study
Next articleScoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C